Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | ERBB3 over exp |
| Therapy | Patritumab deruxtecan |
| Indication/Tumor Type | prostate cancer |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| ERBB3 over exp | prostate cancer | sensitive | Patritumab deruxtecan | Preclinical - Pdx & cell culture | Actionable | In a preclinical study, Patritumab deruxtecan (U3-1402) inhibited growth of patient-derived prostate cancer cells with high ERBB3 (HER3) expression in culture and in a patient-derived xenograft (PDX) model, but did not demonstrate anti-tumor activity in cell lines with low ERBB3 (HER3) expression (PMID: 34753775). | 34753775 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (34753775) | HER3 Is an Actionable Target in Advanced Prostate Cancer. | Full reference... |